Bausch + Lomb Q2 Revenue Jumps 9%, Raises Full-Year Guidance; Pharma and Surgical Profits Surge
BLCO sits 24% above its 52-week low of $13.09.
Summary
Bausch + Lomb posted Q2 2026 revenue of $1.394B (+9% YoY), swung to an operating profit, and raised full-year guidance. Pharma and Surgical segments showed dramatic profit improvement, while interest costs fell. An FDA OAI for the Tampa plant and a failed glaucoma trial add caution.
Key Events · Earnings and Guidance · BLCO
-
Q2 Revenue +9%, Operating Profit Swings Positive
Revenue reached $1.394B, up 9% from $1.278B in Q2 2025. Operating income was $83M versus a loss of $11M last year, driven by higher volumes and pricing across all segments.
-
Full-Year Guidance Raised
Management increased its 2026 outlook, reflecting sustained momentum in Vision Care, Pharmaceuticals, and Surgical. The 8-K filed concurrently confirmed the raise.
-
Pharma Profit Surges 141%, Surgical Returns to Profit
Pharmaceuticals segment profit jumped to $89M from $37M, helped by MIEBO and XIIDRA growth and the absence of prior-year inventory step-up costs. Surgical profit reached $17M vs. $2M, driven by premium IOLs and recovery from the 2025 enVista recall.
-
Interest Expense Drops $35M on Refinancing
Interest expense fell to $93M from $128M, reflecting lower rates on the January 2031 Refinancing Term Facility and the write-off of prior financing costs in 2025.
Analysis · BLCO · Industrial Applications And Services
A strong second quarter saw revenue climb 9% to $1.394 billion, flipping the operating result to an $83 million profit from an $11 million loss a year ago. The Pharmaceuticals segment more than doubled its profit, while Surgical swung back into the black. Reflecting this momentum, management raised full-year guidance. Lower interest expense—thanks to refinancing—and improved cash generation further bolster the balance sheet. On the regulatory front, the FDA issued an OAI for the Tampa facility, and a key glaucoma program failed its Phase 2 trial, adding risk. Meanwhile, the enVista Beyond EDOF lens is under review after topline data, with launch now expected in 2027. The near-term outlook has materially improved, but long-term execution risks remain in focus.
At the time of this filing, BLCO was trading at $16.20 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $5.8B. The 52-week trading range was $13.09 to $18.92. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.